Portola Pharmaceuticals   Print Page    Close Window

We are committed to providing the media with timely and accurate information.

Media Contact:
Patrick Ryan
Pure Communications
pryan@purecommunications.com

Keyword Search
 
2019 | 2018 | 2017 | 2016
DateTitle 
February 07, 2019Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding
– Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients – –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events Observed Among Patients Who Re-started Oral Anticoagulation Therapy – – Data Presented as a Late-Breaking Oral Presentation at the International Stroke Conference 2019 and Published in The New England Journal of Medicine – SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) to... 
Printer Friendly Version
February 01, 2019Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and full year ended December 31, 2018, and provide a general business overview on Friday, March 1, 2019, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call Details The live conference call on Friday, March 1, 2019, at 8:30 a.m. ET, can be accessed by phone by calli... 
Printer Friendly Version
January 30, 2019Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019
Results to be presented on Thursday, February 7, 2019 at 11:36 a.m. HST/4:36 p.m. EST SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] have been accepted as a late-breaking oral presentation during the International Stroke Conference (ISC) 2019. The data will be presented on Thursday, February 7, 201... 
Printer Friendly Version
January 28, 2019Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer
Brings to Portola 30 Years’ Commercial Experience and Key Therapeutic Area Launch Expertise SOUTH SAN FRANCISCO, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately. Mr. Koenig brings to his new role more than three decades of global commercial leadership and operations experience. He will report to Scott Garland, president and c... 
Printer Friendly Version